US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere...
22.12.2014
- Swiss pharmaceutical producer group Roche said it would discontinue a late-stage study of investigational anti-amyloid medicine gantenerumab in pre-dementia Alzheimer's disease...
